Loading organizations...
§ Private Profile · Cambridge, MA, USA
Biotechnology company developing treatments for dystonia and movement disorders.
Vima Therapeutics is a clinical-stage biotechnology company developing novel oral therapies for individuals with movement disorders. The company focuses on pioneering the first oral treatment designed to address dystonia and related conditions, aiming to advance a new era in therapeutic approaches. Its technical strategy centers on identifying and targeting the underlying causes of these neurological disorders.
The company emerged from incubation by Atlas Venture, with Dr. Bernard Ravina serving as its founder and Chief Executive Officer. Vima Therapeutics was established with the insight that current treatments for movement disorders could be significantly improved by developing targeted oral medications that offer greater convenience and efficacy for patients.
Vima Therapeutics’ primary focus is on patients living with dystonia and other movement disorders, striving to provide them with impactful treatments. The company's long-term vision is to enable these individuals to regain their freedom of movement by developing therapies that effectively target the root cause of their conditions.
Vima Therapeutics has raised $160.0M across 2 funding rounds.
Vima Therapeutics has raised $160.0M in total across 2 funding rounds.
Vima Therapeutics has raised $160.0M across 2 funding rounds. Most recently, it raised $100.0M Series A Extension in March 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 11, 2026 | $100M Series A Plus | — | Access Industries, Atlas Venture, Canaan Partners, JOE Cabral | Announced |
| May 1, 2025 | $60M Series A | Atlas Venture | Acorn Bioventures, OrbiMed, Access Industries, Canaan Partners | Announced |
Vima Therapeutics is a clinical-stage biotechnology company developing VIM0423, a potential first-in-class oral therapy targeting the root cause of dystonia and related movement disorders in the central nervous system.[1][2][3][4] It serves patients with these chronic conditions, which lack therapies addressing underlying causes, by advancing an oral treatment currently in Phase 1 trials with Phase 2 planned for Q4 2025; the company launched in May 2025 with a $60M Series A led by Atlas Venture, plus Access Industries and Canaan.[2][4]
Headquartered in Cambridge, Massachusetts, Vima focuses on improving patient movement control through innovative, patient-centered drug development led by movement disorder experts.[3][4][5]
Vima Therapeutics emerged from Atlas Venture's incubator as a seed investment, founded by physicians and scientists with deep expertise in movement disorders, including CEO Bernard Ravina, MD, MS, a neurologist with over 25 years in drug development across government, academia, industry, Biogen, Voyager Therapeutics, and Praxis Medicines.[2][4][5] David Grayzel, MD, partner at Atlas Venture, co-founded and chairs the board, emphasizing a singular focus on transforming dystonia patient lives from inception.[2][4]
The company launched publicly on May 29, 2025, with its $60M Series A, immediately advancing VIM0423 into Phase 1 clinical trials under leadership like head of R&D Judith Dunn.[2][4] This marked a pivotal shift from incubation to clinical-stage operations targeting unmet needs in oral therapies for movement disorders.[1][2]
Vima rides the wave of precision neurology and CNS drug innovation, targeting dystonia—a market with high unmet needs amid growing demand for oral, mechanism-based therapies over injectables.[1][2][4] Timing aligns with advances in muscarinic receptor targeting and biotech funding resurgence, enabling quick clinic entry via incubator models like Atlas Venture's.[2][4]
Market forces favor Vima: rising awareness of movement disorders, aging populations increasing prevalence, and investor interest in high-impact rare diseases with large addressable markets.[1][2] It influences the ecosystem by pioneering oral options, potentially accelerating similar CNS programs and validating VC-backed biotech launches.[3][4]
Vima is poised for Phase 2 initiation in Q4 2025, with potential Phase 3 and partnership opportunities if VIM0423 demonstrates efficacy in dystonia control.[2][4] Trends like AI-driven drug discovery and CNS breakthroughs will shape its path, possibly expanding to related disorders amid competition from similar biotechs.[1][2]
Its influence may grow by proving oral therapies viable for movement disorders, drawing more capital to the space and redefining patient standards—echoing its launch promise to change dystonia lives through root-cause innovation.[2][4]
Vima Therapeutics has raised $160.0M in total across 2 funding rounds.
Vima Therapeutics's investors include Access Industries, Atlas Venture, Canaan Partners, Joe Cabral, Acorn Bioventures, OrbiMed.